The EGFR variant, the most common gene variation in non–small cell lung cancer, is significantly higher among Asian patients with lung cancer than among white patients.26,27,28 Therefore, Asian patients with lung cancer may benefit most from molecular-targeted therapy with the advent of EGFR inhibitors, which have prolonged survival rates considerably.29,30. The gene discussed is EGFR; the disease is lung cancer.